The transforming growth factor β (TGFβ) inhibitor BAMBI (bone morphogenetic protein and activin membrane‐bound inhibitor) has been shown to control differentiation of CD4+ T lymphocytes into either tolerogenic Treg cells or pathogenic Th17 cells, through the regulation of TGFβ and interleukin‐2 (IL‐2) signaling strength. The present study was undertaken to explore the potential beneficial effects of this strategy of pharmacologic inhibition using novel anti‐BAMBI monoclonal antibodies (mAb) in different experimental murine models of chronic skin and joint inflammatory/autoimmune disease.

中文翻译：

---

抗骨形态发生蛋白和激活素膜结合抑制剂对牛皮癣和关节炎的治疗作用。

转化生长因子β（TGFβ）抑制剂BAMBI（骨形态发生蛋白和激活素膜结合抑制剂）已显示可通过调节TGFβ和白介素2来控制CD4 + T淋巴细胞向致耐受性Treg细胞或致病性Th17细胞的分化。 （IL-2）信号强度。本研究旨在探索使用新型抗BAMBI单克隆抗体（mAb）在慢性皮肤和关节炎/自身免疫性疾病的不同实验鼠模型中进行这种药理抑制策略的潜在有益效果。